GI Innovation starts Japan phase 2 trial of allergy drug

What happened: GI Innovation said the first patient in a Japanese phase 2 trial of its allergy treatment candidate GI-301 is scheduled to receive the drug this month. The trial is run by Maruho under a 2023 licensing agreement. Key numbers: Deal worth up to 300 billion won ($221 million) at the time. Maruho founded in 1915. Dermatology about 95 percent of its pharmaceutical sales. Why it matters: GI Innovation is entitled to milestone payments and royalties on sales. The phase 2 study evaluates GI-301, also known as resigercept, in chronic spontaneous urticaria patients.

GI Innovation said the first patient in a Japanese phase 2 trial of its allergy treatment candidate GI-301 is scheduled to receive the drug this month. The trial is run by Maruho under a 2023 licensing agreement.

GI Innovation is entitled to milestone payments and royalties on sales. The phase 2 study evaluates GI-301, also known as resigercept, in chronic spontaneous urticaria patients.